The two new products will be marketed under the Extendryl brand name and will be launched in March 2008.
Extendryl PEM tablets combine two compounds; a decongestant with an anticholinergic/drying agent in an extended release format to provide eight to 12 hours of relief of symptoms for adults suffering from nasal congestion and mucosal drainage associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis, and asthma.
Extendryl GCP oral solution combines three compounds (100mg/5 mL guaifenesin; 15 mg/5mL carbetapentane citrate; 5mg/mL hydrochloride), and is indicated for temporary relief of non-productive cough accompanying respiratory tract congestion associated with the common cold, influenza, sinusitis, and bronchitis.
Frank Greico, CEO of Auriga, said: “These new products further solidify Auriga’s commitment to enhance the Extendryl product line, and the launch is well timed to coincide with the start of spring allergy season. These new additions to the Extendryl family will be a highly synergistic addition to Auriga’s current promotional efforts.”